(iv) increased cross-reactivity with IL-6R from different species such as human and cynomolgus monkey; (v) reduced immunogenicity, for example when administered to a mouse, cynomolgus monkey or human; (vi) increased stability in the presence of proteases, for example (a) in the presence of ...